179 related articles for article (PubMed ID: 35110418)
1. A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
Gounder MM; Rosenbaum E; Wu N; Dickson MA; Sheikh TN; D'Angelo SP; Chi P; Keohan ML; Erinjeri JP; Antonescu CR; Agaram N; Hameed MR; Martindale M; Lefkowitz RA; Crago AM; Singer S; Tap WD; Takebe N; Qin LX; Schwartz GK
Clin Cancer Res; 2022 Apr; 28(8):1586-1594. PubMed ID: 35110418
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).
Means-Powell JA; Mayer IA; Ismail-Khan R; Del Valle L; Tonetti D; Abramson VG; Sanders MS; Lush RM; Sorrentino C; Majumder S; Miele L
Clin Breast Cancer; 2022 Feb; 22(2):103-114. PubMed ID: 34903452
[TBL] [Abstract][Full Text] [Related]
4. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL
Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Sardesai S; Badawi M; Mrozek E; Morgan E; Phelps M; Stephens J; Wei L; Kassem M; Ling Y; Lustberg M; Stover D; Williams N; Layman R; Reinbolt R; VanDeusen J; Cherian M; Grever M; Carson W; Ramaswamy B; Wesolowski R
Invest New Drugs; 2020 Oct; 38(5):1400-1410. PubMed ID: 31953695
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
LoConte NK; Razak AR; Ivy P; Tevaarwerk A; Leverence R; Kolesar J; Siu L; Lubner SJ; Mulkerin DL; Schelman WR; Deming DA; Holen KD; Carmichael L; Eickhoff J; Liu G
Invest New Drugs; 2015 Feb; 33(1):169-76. PubMed ID: 25318436
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.
De Jesus-Acosta A; Laheru D; Maitra A; Arcaroli J; Rudek MA; Dasari A; Blatchford PJ; Quackenbush K; Messersmith W
Invest New Drugs; 2014 Aug; 32(4):739-45. PubMed ID: 24668033
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
[TBL] [Abstract][Full Text] [Related]
11. Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.
Wu J; Lorusso PM; Matherly LH; Li J
Clin Cancer Res; 2012 Apr; 18(7):2066-79. PubMed ID: 22351688
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of RO4929097 in metastatic colorectal cancer.
Strosberg JR; Yeatman T; Weber J; Coppola D; Schell MJ; Han G; Almhanna K; Kim R; Valone T; Jump H; Sullivan D
Eur J Cancer; 2012 May; 48(7):997-1003. PubMed ID: 22445247
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Sahebjam S; Bedard PL; Castonguay V; Chen Z; Reedijk M; Liu G; Cohen B; Zhang WJ; Clarke B; Zhang T; Kamel-Reid S; Chen H; Ivy SP; Razak AR; Oza AM; Chen EX; Hirte HW; McGarrity A; Wang L; Siu LL; Hotte SJ
Br J Cancer; 2013 Aug; 109(4):943-9. PubMed ID: 23868004
[TBL] [Abstract][Full Text] [Related]
15. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
Nair JS; Sheikh T; Ho AL; Schwartz GK
Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
[TBL] [Abstract][Full Text] [Related]
16. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Carr RM; Duma N; McCleary-Wheeler AL; Almada LL; Marks DL; Graham RP; Smyrk TC; Lowe V; Borad MJ; Kim G; Johnson GB; Allred JB; Yin J; Lim VS; Bekaii-Saab T; Ma WW; Erlichman C; Adjei AA; Fernandez-Zapico ME
Pancreatology; 2020 Sep; 20(6):1115-1122. PubMed ID: 32778368
[TBL] [Abstract][Full Text] [Related]
17. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
Wang L; Dai G; Yang J; Wu W; Zhang W
Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
20. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Luistro L; He W; Smith M; Packman K; Vilenchik M; Carvajal D; Roberts J; Cai J; Berkofsky-Fessler W; Hilton H; Linn M; Flohr A; Jakob-Røtne R; Jacobsen H; Glenn K; Heimbrook D; Boylan JF
Cancer Res; 2009 Oct; 69(19):7672-80. PubMed ID: 19773430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
